Immunotherapy is one of the most important areas in modern medicine. Using antibodies, proteins, and cells, physicians are now able to target a range of conditions with specificity. UC San Diego researchers have recently developed a new process for engineering macrophages to possess a broad range of sensing and programed actions for directed therapeutics.
UC San Diego researchers have developed methods and processes for engineering macrophages to carry both response elements and effector modules that can provide directed immunotherapy. By modulating the cellular response profile, macrophages can now target cells that would otherwise evade detection and clearance. By relying on the natural phagocytic process, the therapeutic potential of this technology is enhanced and the off-target risks may be minimized.
Potential use in directed therapeutics for immunotherapy.
By relying on the natural phagocytic process, the therapeutic potential of this technology is enhanced and the off-target risks may be minimized.
A provisional patent has been submitted.
|United States Of America||Published Application||0140834-A1||05/07/2020||2017-142|
|Patent Cooperation Treaty||Published Application||2019014419||01/17/2019||2017-142|